Extended-Release Steroidal Injectable Suspension Available for Knee OA

This article originally appeared here.
Share this content:
Triamcinolone acetonide binds to and activates the glucocorticoid receptor, leading to activation of anti-inflammatory transcription factors.
Triamcinolone acetonide binds to and activates the glucocorticoid receptor, leading to activation of anti-inflammatory transcription factors.

Flexion Therapeutics announced the availability of Zilretta (triamcinolone acetonide extended-release injectable suspension) indicated for the management of pain associated with osteoarthritis (OA) of the knee. 

Zilretta, approved in October 2017, consists of an extended-release microsphere formulation for intra-articular injection. It combines a short-acting corticosteroid with a poly lactic-co-glycolic acid (PLGA) matrix to provide pain relief over 12 weeks. 

Triamcinolone acetonide binds to and activates the glucocorticoid receptor, leading to activation of anti-inflammatory transcription factors such as lipocortins and inhibition of inflammatory transduction pathways by blocking the release of arachidonic acid and preventing the synthesis of prostaglandins and leukotrienes.

Zilretta is not intended for repeat administration. It is available as a single-dose kit containing a vial of microsphere powder (32mg triamcinolone acetonide), diluent, and a vial adapter.

Reference

Flexion therapeutics announces full commercial launch and nationwide availability of ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) [press release]. Burlington, MA:Flexion Therapeutics. Published November 20, 2017. Accessed November 22, 2017.



You must be a registered member of Rheumatology Advisor to post a comment.